P16 reactivation induces anoikis and exhibits antitumour potency by downregulating Akt/survivin signalling in hepatocellular carcinoma cells

Gut

Volumn 60, Issue 5, 2011, Pages 710-721

  Hu, Huanzhang ^a,b   Li, Zhigang ^c   Chen, Jie ^c   Wang, Duanming ^a,d   Ma, Juming ^e   Wang, Weiguo ^e   Li, Jiang ^a   Wu, Hongping ^a   Li, Linfang ^a   Wu, Mengchao ^a   Qian, Qijun ^a   Chen, Jingbo ^d   Su, Changqing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUZHOU GENERAL HOSPITAL   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d SHIHEZI UNIVERSITY   (China)

^e The 117th Hospital of Chinese PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYCLIN DEPENDENT KINASE 4; PROTEIN KINASE B; PROTEIN P16; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOIKIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE THERAPY;

ANIMALS; ANOIKIS; CELL CYCLE; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; GENES, P16; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953755891     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.220020     Document Type: Article

References (39)

1. Cánepa ET, Scassa ME, Ceruti JM, et al. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 2007;59:419-26. (Pubitemid 47123998)
2. Coqueret O. Linking cyclins to transcriptional control. Gene 2002;299:35-55. (Pubitemid 35379826)
3. Allay JA, Steiner MS, Zhang Y, et al. Adenovirus p16 gene therapy for prostate cancer. World J Urol 2000;18:111-20.
4. Ma J, He X, Wang W, et al. E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumour effect on gastric cancer. Dig Dis Sci 2009;54:1425-31.
5. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anticancer therapy. Cancer Treat Rev 2009;35:553-62.
6. Sah NK, Khan Z, Khan GJ, et al. Structural, functional and therapeutic biology of survivin. Cancer Lett 2006;244:164-71. (Pubitemid 44485888)
7. Andersen MH, Svane IM, Becker JC, et al. The universal character of the tumour-associated antigen survivin. Clin Cancer Res 2007;13:5991-4. (Pubitemid 350075053)
8. Yamashita S, Masuda Y, Kurizaki T, et al. Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 2007;27:2803-8. (Pubitemid 47228001)
9. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007;28:1133-9. (Pubitemid 47062670)
10. Johnson ME, Howerth EW. Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol 2004;41:599-607. (Pubitemid 39573750)
11. Cheung CH, Chen HH, Kuo CC, et al. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer 2009;8:43.
12. Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med 2005;9:360-72.
13. Rödel F, Frey B, Leitmann W, et al. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 2008;71:247-55. (Pubitemid 351491424)
14. Hansen JB, Fisker N, Westergaard M, et al. SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther 2008;7:2736-45.
15. Yang CT, Li JM, Weng HH, et al. Adenovirus-mediated transfer of siRNA against survivin enhances the radiosensitivity of human non-small cell lung cancer cells. Cancer Gene Ther 2010;17:120-30.
16. Zaffaroni N, Pennati M, Folini M. Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small-interfering RNAs. Methods Mol Biol 2007;361:239-63. (Pubitemid 350183211)
17. Giaccone G, Zatloukal P, Roubec J, et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009;27:4481-6.
18. Sun Y, Lin R, Dai J, et al. Suppression of tumour growth using antisense oligonucleotide against survivin in an orthotopic transplant model of human hepatocellular carcinoma in nude mice. Oligonucleotides 2006;16:365-74. (Pubitemid 46043155)
19. Kojima H, Iida M, Yaguchi Y, et al. Enhancement of cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene. Arch Otolaryngol Head Neck Surg 2006;132:682-5. (Pubitemid 43927048)
20. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008;12:463-76. (Pubitemid 351551639)
21. Douma S, Van Laar T, Zevenhoven J, et al. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004;430:1034-9.
22. He X, Ota T, Liu P, et al. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res 2010;70:3109-18.
23. Su C, Peng L, Sham J, et al. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumour activity in immunodeficient and immunocompetent mice. Mol Ther 2006;13:918-27.
24. Shimamoto S, Takata M, Tokuda M, et al. Interactions of S100A2 and S100A6 with the tetratricopeptide repeat proteins, Hsp90/Hsp70-organizing protein and kinesin light chain. J Biol Chem 2008;283:28246-58.
25. Muşat M, Vax VV, Borboli N, et al. Cell cycle dysregulation in pituitary oncogenesis. Front Horm Res 2004;32:34-62.
26. Kroemer G, Galluzzi L, Vandenabeele P, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009;16:3-11.
27. Gilmore AP. Anoikis. Cell Death Differ 2005;12:1473-7.
28. Ohtani N, Yamakoshi K, Takahashi A, et al. The p16INK4a-RB pathway: molecular link between cellular senescence and tumour suppression. J Med Invest 2004;51:146-53. (Pubitemid 39610908)
29. Ai MD, Li LL, Zhao XR, et al. Regulation of survivin and CDK4 by EpsteineBarr virus encoded latent membrane protein 1 in nasopharyngeal carcinoma cell lines. Cell Res 2005;15:777-84. (Pubitemid 41653915)
30. Suzuki A, Hayashida M, Ito T, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene 2000;19:3225-34. (Pubitemid 30487409)
31. Li F, Yang J, Ramnath N, et al. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005;114:509-12.
32. Connell CM, Wheatley SP, McNeish IA. Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis. Cancer Res 2008;68:7923-31.
33. Liu F, Matsuura I. Inhibition of Smad antiproliferative function by CDK phosphorylation. Cell Cycle 2005;4:63-6. (Pubitemid 41038929)
34. Wall NR, O'Connor DS, Plescia J, et al. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumour cell apoptosis. Cancer Res 2003;63:230-5. (Pubitemid 36070444)
35. Schrage YM, Lam S, Jochemsen AG, et al. Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro. J Cell Mol Med 2009;13:2843-52.
36. Ripka S, Neesse A, Riedel J, et al. CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut 2010;59:1101-10.
37. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-95. (Pubitemid 34214843)
38. Filippa N, Sable CL, Filloux C, et al. Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase. Mol Cell Biol 1999;19:4989-5000. (Pubitemid 29289538)
39. Pekarsky Y, Koval A, Hallas C, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci USA 2000;97:3028-33. (Pubitemid 30183249)